


# A SAFE TRANSITION OF CARE

*Clinicians Expect It - Patients Deserve It*

## THE PROBLEM

**90 PATIENTS DIE EACH DAY** in the US due to Bloodstream Infections (BSIs)<sup>1</sup>

A study by the Ochsner Health System showed a one year baseline rate of .963 per 1,000 line days, (20 infections/20,773 line days) similar to infection rates found in a systematic review comparing line types.<sup>2</sup>



## THE COST



**COST PER BLOODSTREAM INFECTION**

**\$3,700-\$39,000 PER EPISODE<sup>4</sup>**




## THE CAUSE

Regardless of device, resident bacteria from the patient's own skin quickly recolonize.<sup>5</sup>



**Patients need to be protected from their own skin's microflora.<sup>5</sup>**




Patient Risk of Infection: ■ Low ■ Medium ■ High

## Studies show there are risks of BSIs in the home setting

Rinke and colleagues evaluated central line maintenance practices in outpatient pediatric oncology patients and found that none of the home care agencies surveyed utilized comprehensive definitions for monitoring CLABSIs and that only 25 percent of agencies knew their overall CLABSI rate.<sup>6</sup>

**The conclusion of the CLABSI study was:**




**2X** more CLABSIs occurred in the ambulatory setting than the inpatient setting.<sup>6</sup>


# THE SOLUTION

## The #1 selling CHG dressing on the market with a 1A CDC recommendation.<sup>7</sup>

Through its proprietary delivery technology, BIOPATCH® provides proven sustained antimicrobial action for 7 days<sup>8</sup>



Continuous release of CHG provides 360° protection for 7 days - for ongoing antisepsis between dressing changes<sup>8</sup>



With BIOPATCH Disk, post-prep environment extends for up to 7 days.<sup>8</sup>  
 Patient Risk of Infection: ■ Low ■ Medium ■ High

## We offer the only IV site dressing that is:<sup>9-11</sup>

- **Easy to apply and remove**
- **360° degree coverage** around the insertion site
- **Proprietary Urethane composite material** designed to continuously release CHG over 7 days to maintain skin antisepsis while absorbing 8x its own weight in fluid
- **FDA-cleared indication** to reduce local infections, catheter-related blood stream infections (CRBSI), and skin colonization of microorganisms commonly related to CRBSI in patients with central nervous and arterial catheters, meeting the requirements of a CDC 1A recommendation for prevention of intravascular catheter-related infections

Protect All Lines.  
 Protect All Lives.<sup>TM</sup>



Order Code	4150	4151	4152
<b>Size</b>	1" disc (2.5cm) w/4.0mm center hole	3/4" disc (1.9cm) w/1.5mm center hole	1" disc (2.5cm) w/7.0mm center hole
<b>French Size Range</b>	6-12Fr	<6Fr	13-20Fr
<b>Common Uses</b>	Central Lines PICC	Peripheral IVs Huber Needles (ports) Arterial Lines Extended Dwell PIVs Midlines PICCs Pins	Dialysis Catheters Drains Sheaths Cordis Catheters VAD drive lines
<b>Quantity per Case</b>	10/box 4 boxes/case, 40	10/box 4 boxes/case, 40	10/box 4 boxes/case, 40

**References:** 1. Do No Harm - Prevent Central Line Associated Bloodstream Infections, Joint Commission, [https://www.jointcommission.org/assets/1/6/CLABSII\\_infographic\\_final.pdf](https://www.jointcommission.org/assets/1/6/CLABSII_infographic_final.pdf). Accessed 27 Mar 2019. 2. Baumgarten K, et al. Bridging the Gap: A Collaborative to Reduce Peripherally Inserted Central Catheter Infections in the Home Care Environment. The Ochsner Journal 2013;13:352-358. 3. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159-1171. 4. Infection Control and Hospital Epidemiology, Vol. 35, No. 7 (July 2014), pp. 753- 771 5. Hendley JO, Ashe KM. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin. Antimicrobial Agents and Chemotherapy. April 1991;35(4):627-631 6. Rinke et al. Ambulatory Pediatric Oncology CLABSIs: Epidemiology and Risk Factors. Pediatric Blood Cancer 2013 Nov;60(11):1882-9. doi:10.1002/psc.24677. Epub 2013 Jul 23. 7. 2017 Updated Recommendations on the Use of Chlorhexidine-Impregnated Dressings for Prevention of Intravascular Catheter-Related Infections Published Nov 1, 2017. 8. Bhende MS, Rothenburger S. In vitro antimicrobial effectiveness of 5 catheter insertion-site dressings. The Journal of the Association for Vascular Access. 2007; 12(4):227-231. 9. BIOPATCH® Protective Disk with CHG. Instructions for Use, Ethicon, INC, 2011 10. Westergom C. Ex Vivo Comparative Analysis of Chlorhexidine Gluconate (CHG) Coverage on Porcine Skin. Ethicon, Inc, Somerville, NJ, 2008. 11. Shapiro JM, Bond EL, Garman JK. Use of a chlorhexidine dressing to reduce microbial colonization of epidural catheters. Anesthesiology. 1990 Oct;73(4):625-31.